Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data.
Truist Financial analyst Joon Lee maintained a Buy rating on Solid Biosciences (SLDB – Research Report) today. The company’s shares closed ...
JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Solid Biosciences (SLDB – Research Report) today and set a price target of ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...
CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing ...